Baseline eosinophil level may be a predictive indicator for the effectiveness of dupilumab in patients with prurigo nodularis : A single-center, real-world prospective study
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:90 |
|---|---|
| Enthalten in: |
Journal of the American Academy of Dermatology - 90(2024), 5 vom: 15. Apr., Seite 1076-1078 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yi, Xiaoqing [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
420K487FSG |
|---|
| Anmerkungen: |
Date Completed 15.04.2024 Date Revised 15.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jaad.2024.01.036 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368328449 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368328449 | ||
| 003 | DE-627 | ||
| 005 | 20240415233142.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240213s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jaad.2024.01.036 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1376.xml |
| 035 | |a (DE-627)NLM368328449 | ||
| 035 | |a (NLM)38296194 | ||
| 035 | |a (PII)S0190-9622(24)00136-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yi, Xiaoqing |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Baseline eosinophil level may be a predictive indicator for the effectiveness of dupilumab in patients with prurigo nodularis |b A single-center, real-world prospective study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.04.2024 | ||
| 500 | |a Date Revised 15.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a adverse events | |
| 650 | 4 | |a biologics | |
| 650 | 4 | |a clinical efficacy | |
| 650 | 4 | |a dupilumab | |
| 650 | 4 | |a prurigo nodularis | |
| 650 | 4 | |a real-world | |
| 650 | 7 | |a dupilumab |2 NLM | |
| 650 | 7 | |a 420K487FSG |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 700 | 1 | |a Cao, Qiaozhi |e verfasserin |4 aut | |
| 700 | 1 | |a Peng, Cong |e verfasserin |4 aut | |
| 700 | 1 | |a Jia, Qiqi |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Jie |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the American Academy of Dermatology |d 1984 |g 90(2024), 5 vom: 15. Apr., Seite 1076-1078 |w (DE-627)NLM000422703 |x 1097-6787 |7 nnns |
| 773 | 1 | 8 | |g volume:90 |g year:2024 |g number:5 |g day:15 |g month:04 |g pages:1076-1078 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jaad.2024.01.036 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 90 |j 2024 |e 5 |b 15 |c 04 |h 1076-1078 | ||